Hormonal
Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) produce significantly greater body weight loss and higher rates of prediabetes-to-normoglycemia conversion compared to GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and placebo in non-diabetic obese individuals.
If you have obesity or are overweight without diabetes, a once-weekly dual-acting injection (tirzepatide) can lead to significant weight loss (up to 21% in trials) and often reverses prediabetes. This is more effective than older GLP-1 drugs. It requires lifestyle changes alongside the medication.
Due to impressive BW loss in nondiabetic obese, who received tirzepatide, this agent will presumably affect T2DM risk and reversion of prediabetes. ... The SURMOUNT-1 trial ... showed that treatment with tirzepatide (5, 10, and 15 mg, OW SC) induced substantial and sustained BW loss (the mean percentage change in BW -15.0%, -19.5%, -20.9%, respectively). ... Furthermore, most of the prediabetes patients (95.3%) at baseline, treated with tirzepatide, had reverted to normoglycemia, when compared with 61.9% of patients treated with placebo.
Why this rating
Based on large-scale, randomized, double-blind phase 3 clinical trials (SURMOUNT-1, STEP-1, SCALE) with statistically significant results.
Source
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence
Emir Muzurović et al. · Journal of Cardiovascular Pharmacology and Therapeutics · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →